Figure 5.
Strategies for targeting LNPs to various organs, including the heart, eye, and utero
(A) Schematic of LNP Delivery of modified mRNA to damaged myocardium.
(B) Luciferase activity in various organ lysates 4 h after LNP-mRNA administration.
(C) Schematic of LNP and Cre mouse model, depicting both tested routes of administration.
(D) Expression of MH42-conjugated LNPs in the neural retina.
(E) Overview of LNPs for fetal delivery.
(F) GFP expression in fetal livers 24 h after injection with LNPs A-3.GFP. (A and B) Reproduced from permission.99 Copyright 2022, Elsevier.
(C and D) Reproduced from permission.102 Copyright 2023, American Association for the Advancement of Science.
(E and F) Reproduced from permission.103 Copyright 2021, American Association for the Advancement of Science.